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Introduction
a major problem in prosthetic joint infection 
(PJI) is the lack of a generally used classifi­
cation system although several different sys­
tems have been proposed in the literature.1,2 
The most frequently used classification of PJIs 
with early, delayed, and chronic infection 
proposed by Schafroth et al3 only focusses on 
the time of onset of infection symptoms. 
However, PJIs are multifactorial complications 
after arthroplasty and involve different param­
eters, such as the host, the implant with the 
surrounding soft tissue and bone, as well as 
the causative microorganisms, which are of 
relevance for the treatment strategy and final 
outcome for the patient.4,5 Therefore, these 
parameters should be taken into account in 
a classification concept for PJIs. McPherson 
et al6 came up with a proposal for a staging 
system for PJIs that includes three categories: 
infection type (acute versus chronic), systemic 
host grade, and local extremity grade with sig­
nificant correlation between the staging sys­
tem and outcome parameters, particularly 
the relation of complication rates with wors­
ening medical condition and a worsening local 
wound. This classification does not address 
the causative agent and the underlying imp­
lant, which both have an impact on the treat­
ment decision process and outcome of PJIs. In 
conclusion, there is a strong need for an 
improvement in the classification of PJIs and 
the current editorial is intended to present a 
new idea for a new classification system for PJIs.
In general, new classification systems 
should allow professionals to derive treat­
ment guidelines and prognosis for the dis­
ease. another important aspect is that they 
should not be too complicated as this could 
prevent their use in clinical practice. on the 
other side, the use of established principles 
of other classification systems could help to 
enhance acceptance of a new classification.
one of the most widely and most success­
fully used classification systems in medicine is 
the TNM classification for malignant tumours 
in oncology. The basics of this system were 
developed in the late 1940s and early 1950s 
by Pierre Denoix and its eighth version was 
recently published in 2017,7 which is used 
globally for the majority of malignant tumours. 
The principle of the TNM system is based on 
details of the primary tumour (T), regional 
lymph nodes (N), and distant metastasis (M). 
For each item, further details regarding the size 
and/or extent of the local tumour (T0 to T4), 
involvement of regional lymph nodes (N0 to 
N3), and differentiation on distant metastasis 
(M0 to M1) are used to guide treatment. 
Furthermore, the TNM system provides infor­
mation for survival and helps to compare 
treatment outcomes from a clinical and scien­
tific perspective. all these aspects are also of 
relevance for PJIs and the frequently used 
sentence “treat the infection like a tumour” 
describes certain similarities between tumours 
and PJIs, in particular the need for resection of 
affected tissue. These aspects have prompted 
the authors of this editorial to present the idea 
for a TNM classification for PJIs.
The above­mentioned crucial parameters 
for PJIs: type of implant including surroun­
ding soft tissue conditions, the causative 
microorganism, and the host were taken 
into account and transferred to the three 
significant letters T, N, and M, which are the 
keystones of the TNM classification system 
in oncology and which are also used for the 
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PJI­TNM classification. ‘T’ represents the local situation 
of the tissue and the indwelling implant, ‘N’ stands for 
the causative non­human bacterial and/or fungal organ­
isms, and ‘M’ for the morbidity of the patient for this 
new PJI­TNM classification. as with TNM in oncology, 
each item is further specified by numbers with increas­
ing severity of the respective item, from 0 to 2 for T and 
N and from 0 to 3 for M. This is detailed in the accompa­
nying infographic in this issue of Bone & Joint Research.8
Regarding the infected joint of the PJI, the name of the 
affected joint is put in front of the TNM letters in order to 
clearly state the affected body region, such as hip, knee, 
and shoulder. If it is a recurrence of infection, the letter ‘r’ 
is put additionally in front of the affected joint in order to 
emphasize reinfection.
t – tissue and implant conditions
local soft tissue and implant conditions are described and 
classified with the letter ‘T’ and significantly influence 
the treatment decision. T0 characterizes a situation with 
healthy soft tissue envelope (or small soft tissue defect not 
requiring plastic surgery coverage) with a stable implant. 
In T1 situations, the implant is loosened but sufficient soft 
tissue coverage is given. T2 cases are characterized by 
severe soft tissue requiring plastic surgery. For each item, 
the small letters ‘a’ and ‘b’ are used for the specification of 
the implant in order to allow for differentiation of stand­
ard implants (‘a’) versus revision implants (‘b’).
n – non-human cells (bacteria and/or fungi)
Microbiological conditions and findings are considered in 
this category. It does not mainly focus on established but 
problematic classifications, such as early, late, acute, or 
chronic, but more on biofilm and antibiotic resistance 
profiles of the causative germs. N0 stands for an infection 
with immature biofilm formation. This is further specified 
to N0a and N0b as the pathogenesis in early postopera­
tive (N0a) versus late haematogenous (N0b) should be 
acknowledged. N1 and N2 represent situations with 
mature biofilm formation, in which N1a stands for mature 
biofilm formation with ‘non­difficulty to treat organisms’ 
with bacteria being susceptible to biofilm­active antibiot­
ics (e.g. rifampicin in staphylococci or fluoroquinolones 
in gram­negative bacteria).9 In a so­called culture­negative 
infection, N1b is used. Infections with mature biofilm for­
mation with difficult­to­treat bacteria (N2a) with resist­
ance to the aforementioned antibiotics, polymicrobial 
infection (N2b), or fungi (N2c) are summarized under 
category N2.
M – Morbidity of the patient
The morbidity of the patient is of extreme importance for 
the treatment and prognosis of PJI and also for compari­
son of patient cohorts in clinical studies10 and is, there­
fore, an integral part of this current classification as well.
The letter ‘M’ addresses the general health status of the 
patient using the Charlson Comorbidity Index as it enables 
reliable classification of the general health status of the 
host.11 M0 patients are systemically not or only moderately 
compromised with a Charlson Comorbidity Index of 0 or 1. 
Patients with a comorbidity index of 2 to 3 are classified as 
moderately compromised M1 patients. M2 represents 
severely compromised hosts with a Charlson Comorbidity 
Index of 4 to 5. Patients who refuse surgical treatment 
(M3a) or would not benefit (M3b) or not survive surgical 
treatment (M3c) are categorized as M3 patients.
treatment guidelines derived from  
the PJI-tnM system
each classification should be able to derive treat ment 
guidelines for specific situations. The PJI­TNM system 
offe rs this possibility with the following general 
recommendations.
In T0N0 cases, implant retention with irrigation and 
debridement can be considered as no mature biofilm for­
mation, no difficult­to­treat bacteria, no soft tissue com­
promises, and a stable implant are present.
In all T1, T2, N1, and N2 cases, implant removal should 
be recommended due to loosened implants, severely 
compromised soft tissue, and/or major biofilm formation 
or fungi involvement.
M3a patients are not eligible for surgery and M3b 
hosts should be treated less aggressively as they do not 
benefit from major surgical treatment. M3c patients can­
not be operated on due to host restrictions and are only 
eligible for non­surgical treatment, such as antibiotic 
suppression therapy.
There are certain limitations of this new classification. 
First, there is a risk of confusion of PJIs with malignant 
tumour disease when a patient’s PJI is classified with the 
TNM system. However, the prefix PJI and the addition of 
the affected joint should minimize this risk.
Second, the use of the maturity of biofilm formation in 
the ‘N’ section cannot resolve the problem that exact 
time differentiation between immature and mature for­
mation remains difficult to ascertain with current diag­
nostic methods. Nevertheless, its use is a step forward in 
the classification of PJIs, as it eliminates the need to limit 
classification to ‘early’ and ‘late’ and focusses more on 
the bacterial aspects of the underlying infection as men­
tioned above.
Furthermore, the use of the three letters T, N, and M 
with further sub­specification makes the classification 
more difficult to use than the simple differentiation bet­
ween early, delayed, and late and seems to limit its prac­
tical use in daily clinical routine. However, the complexity 
of PJIs including details of the local infection situation, 
causative agent and biofilm maturity, plus the host 
comorbidity, justify a more detailed description of the 
situation.
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In the next step, validation of this new PJI­TNM system 
regarding its accuracy and reliability in clinical routine is 
required, which is to be conducted by a planned pro­
spective clinical trial.
In conclusion, we believe that this system contributes 
to significant improvements in the classification of PJIs for 
clinical routine and clinical studies in PJIs.
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